Q1 2026 results drop Friday, May 1 before market open

CBOE Global Markets operates options and securities exchanges around the world. The flagship business is the Chicago Board Options Exchange — the largest US options exchange — which holds exclusive licenses on S&P 500 (SPX) options and the VIX index. They also run equity markets, futures, FX, and a recurring-revenue data and analytics business called DataVantage.

The thesis is straightforward: CBOE is a toll road on options trading, and options volume is structurally growing faster than equity volume. The SPX and VIX licenses are a moat no competitor can replicate. Add a recurring data business, high operating leverage, and a clean balance sheet, and you get a financial that compounds during volatility and keeps grinding higher when it's quiet.

Now the timing. CBOE reports Q1 Friday morning, and three signals have lined up that I want timestamped before the tape moves.

Consensus EPS for Q1 sits at $3.34, revised meaningfully higher over the past 30 days. CBOE has beaten consensus in each of the last four quarters. The most accurate analyst estimates are tracking above consensus, which historically points to another beat. That's the methodology stack — rising estimate revisions + a clean beat history + analysts trending higher into the print. On record now, not after Friday's tape.

Here's the trailing trajectory:

Growth accelerated meaningfully through 2025. Q4 was the standout — derivatives net revenue up 38% YoY on record options volumes. Q1 2026 consensus implies that pace mostly holds.

Cash generation tells a similar story, with one caveat:

That OCF jump is materially larger than net income growth (~24%), which is partly working capital timing — exchange businesses can have weird quarter-to-quarter swings on clearing balances and customer collateral. The full-year number is directionally reliable; I wouldn't extrapolate a 60% growth rate forward.

Index options — SPX and VIX — are a quasi-monopoly. Options net revenue was $433M in Q4, about 65% of total. That franchise carries the rest of the business, and 0DTE growth keeps pushing volumes higher: Q1 2025 index options ADV was up 29% YoY, and these are the highest-margin contracts in the building. Q4 2025 saw another set of volume records.

DataVantage (the recurring data and analytics segment) grew 9% in Q4 — slower than trading, but it's the durable subscription stream that makes the multi-cycle compounding case work. Management's 2026 guide for DataVantage is mid-to-high single digit growth.

Balance sheet is clean. $2.2B adjusted cash, 0.9x leverage. Plenty of dry powder for buybacks, dividends, or selective M&A.

That 65% derivatives concentration is both the moat and the risk. If anything ever cracks the SPX/VIX licensing exclusivity, the multiple compresses fast. The multi-list options space (SPY, QQQ, individual equity options) is structurally competitive — CBOE shares that market with Nasdaq, MIAX, and others, and fee pressure there is a real ongoing drag.

The 2026 guidance is the second wrinkle. Management guided "mid single-digit" organic net revenue growth — a meaningful step down from 17% in 2025. About 3 points of that deceleration is strategic: they're winding down operations in Canada and Australia and exiting the FedEx clearing arrangement, all of which they're calling a "net revenue headwind." Strip those out and organic growth is closer to high single digit. But the headline 2026 number will optically look like a slowdown, and that's worth flagging.

The signal stack is clean going into Friday. Estimate revisions, analyst trend, and beat history all point the same direction. The bull thesis is durable. The bear case is real but it's concentration risk I can size around, not a thesis-killer.

Buy. Position size per methodology. Time horizon: through Q2 earnings minimum. If Friday prints below consensus AND post-print revisions go negative, I revisit publicly.

Friday morning will tell me if the methodology held up here. Either way, it'll be on the track record page by Monday.